Literature DB >> 29258072

Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma.

Naoshi Nishida1, Masatoshi Kudo.   

Abstract

During tumor development, several immunosuppressive molecules are released from cancer cells and contribute to the establishment of immunosuppressive tumor environment. In tumor tissues, cytokines, chemokines, growth factors, and metabolites are present and could counter the effects of immune checkpoint inhibitors. From this point of view, monotherapy of anti-PD-1/PD-L1 antibody might not be enough to exert a sufficient antitumor effect; additional blockade of immunosuppressive molecules in tumor microenvironment could enhance the antitumor effect of anti-PD-1/PD-L1 antibody. Importantly, the production of immunosuppressive molecules in cancer cells is attributed to the activation of cellular signaling through genetic and epigenetic alterations and environmental stimulation, such as inflammation and hypoxia. In this review, we focus on the establishment of immunosuppressive microenvironment of hepatocellular carcinoma in the context of activation of oncogenic signals, and discuss how the immunosuppressive condition could be overcome using tyrosine kinase inhibitors.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Hepatocellular carcinoma; Immune checkpoint inhibitors; Microenvironment; Molecular targeting agent; Oncogene

Mesh:

Year:  2017        PMID: 29258072     DOI: 10.1159/000481246

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  23 in total

Review 1.  Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.

Authors:  Nicholas Borcherding; Ryan Kolb; Jodi Gullicksrud; Praveen Vikas; Yuwen Zhu; Weizhou Zhang
Journal:  J Mol Biol       Date:  2018-05-22       Impact factor: 5.469

2.  Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.

Authors:  Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-17       Impact factor: 11.740

3.  MiR-1179 represses cell proliferation, migration and invasion of hepatocellular carcinoma through suppression of NUAK2.

Authors:  Dejun Wang; Xue Song; Nan Zhang; Yesong Guo
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 4.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405

5.  Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.

Authors:  Jingrui Wang; Sunbin Ling; Jie Ni; Yafeng Wan
Journal:  BMC Cancer       Date:  2022-06-10       Impact factor: 4.638

6.  miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.

Authors:  Caifeng Liu; Jun Li; Wei Wang; Xingyang Zhong; Feng Xu; Junhua Lu
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

7.  Novel Bradykinin Receptor Inhibitors Inhibit Proliferation and Promote the Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the ERK Pathway.

Authors:  Yiou Wang; Bingxue Zhang; Yibing Huang; Wenjun Yao; Fei Tao; Yuxin Chen
Journal:  Molecules       Date:  2021-06-26       Impact factor: 4.411

Review 8.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029

9.  Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.

Authors:  Christine Haider; Julia Hnat; Roland Wagner; Heidemarie Huber; Gerald Timelthaler; Markus Grubinger; Cédric Coulouarn; Wolfgang Schreiner; Karin Schlangen; Wolfgang Sieghart; Markus Peck-Radosavljevic; Wolfgang Mikulits
Journal:  Hepatology       Date:  2018-12-20       Impact factor: 17.425

Review 10.  Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.

Authors:  Zeli Yin; Keqiu Jiang; Rui Li; Chengyong Dong; Liming Wang
Journal:  Mol Cancer       Date:  2018-12-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.